HAVCR2 and acute myeloid leukemia: An in vitro experiment using murine AML cells demonstrated that co-expression of TIM-3 and PD-1 on CD8-positive T cells was enhanced during disease progression and inhibition of either molecule alone did not attenuate tumor activity [35].